LON:CLL - Cello Health plc (CLL.L) Stock Price Target and Predictions

  • Consensus Rating: N/A
  • Consensus Price Target: GBX 0
  • Forecasted Upside: -100.00 %
  • Number of Analysts: 0
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
GBX 161
+0.30 (1.20%)

This chart shows the closing price for CLL by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Cello Health plc (CLL.L) Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for CLL and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for CLL

Analyst Price Target is GBX 0
▼ -100.00% Downside Potential
This price target is based on 0 analysts offering 12 month price targets for Cello Health plc (CLL.L) in the last 3 months. The average price target is GBX 0, with a high forecast of GBX 0 and a low forecast of £100,000. The average price target represents a -100.00% upside from the last price of GBX 161.

This chart shows the closing price for CLL for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is N/A

The current consensus among 0 polled investment analysts is to n/a stock in Cello Health plc (CLL.L). This rating has held steady since May 2021, when it changed from a Hold consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart

  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
2/12/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
5/12/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
8/10/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
11/8/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
2/6/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
5/7/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
7/6/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
8/5/2021

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
5/20/2020Liberum CapitalReiterated RatingHoldGBX 120
5/20/2020FinnCapReiterated RatingCorporate
4/8/2020Liberum CapitalLower Price TargetHoldGBX 125 ➝ GBX 120
4/7/2020FinnCapReiterated RatingCorporate
3/19/2020FinnCapReiterated RatingCorporate
3/18/2020Liberum CapitalReiterated RatingHold
2/6/2020Liberum CapitalReiterated RatingHold
1/17/2020FinnCapReiterated RatingCorporate
1/16/2020Liberum CapitalReiterated RatingHold
9/30/2019Liberum CapitalInitiated CoverageHoldGBX 135
9/24/2019FinnCapReiterated RatingCorporate
8/21/2019FinnCapBoost Price TargetCorporateGBX 145 ➝ GBX 160
7/18/2019FinnCapReiterated RatingCorporate
5/8/2019FinnCapReiterated RatingCorporate
3/27/2019FinnCapReiterated RatingCorporate
3/21/2019FinnCapReiterated RatingCorporate
1/17/2019FinnCapReiterated RatingCorporate
9/19/2018FinnCapReiterated RatingCorporate
7/23/2018FinnCapReiterated RatingCorporate
5/9/2018FinnCapReiterated RatingCorporate
12/4/2017FinnCapReiterated RatingBuyGBX 135
9/26/2017FinnCapReiterated RatingBuyGBX 132
9/20/2017N+1 SingerReiterated RatingBuyGBX 131
9/20/2017FinnCapReiterated RatingBuyGBX 132
7/18/2017FinnCapReiterated RatingBuyGBX 132
6/19/2017FinnCapReiterated RatingBuyGBX 132
5/9/2017N+1 SingerReiterated RatingBuyGBX 131
5/9/2017FinnCapReiterated RatingBuyGBX 132
3/22/2017N+1 SingerReiterated RatingBuyGBX 131
3/22/2017FinnCapReiterated RatingBuyGBX 132
3/10/2017FinnCapReiterated RatingBuyGBX 132
2/7/2017FinnCapReiterated RatingBuyGBX 132
2/1/2017FinnCapReiterated RatingBuyGBX 132
1/19/2017FinnCapReiterated RatingBuyGBX 132
1/11/2017Peel HuntReiterated RatingBuyGBX 130
11/17/2016FinnCapReiterated RatingBuyGBX 132
10/19/2016Peel HuntReiterated RatingBuyGBX 130
10/4/2016FinnCapReiterated RatingBuyGBX 132
9/28/2016FinnCapInitiated CoverageBuyGBX 132
9/20/2016N+1 SingerReiterated RatingBuyGBX 127 ➝ GBX 128
9/14/2016N+1 SingerReiterated RatingBuy
9/14/2016Cenkos SecuritiesReiterated RatingBuy
(Data available from 8/5/2016 forward)
Cello Health plc (CLL.L) logo
Cello Health plc, together with its subsidiaries, provides marketing services in the United Kingdom, Rest of Europe, the United States, and internationally. It operates in two segments, Cello Health and Cello Signal. The Cello Health segment offers market research, consulting, and communications services principally to the pharmaceutical and healthcare clients. The Cello Signal segment provides market research and direct communications services principally to consumer-facing clients. Cello Health plc was incorporated in 2004 and is headquartered in London, the United Kingdom.
Read More

Today's Range

Now: GBX 161
Low: 161
High: 161

50 Day Range

MA: GBX 161
Low: 161
High: 161

52 Week Range

Now: GBX 161
Low: 100
High: 165

Volume

N/A

Average Volume

453,244 shs

Market Capitalization

£178.84 million

P/E Ratio

N/A

Dividend Yield

1.34%

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of Cello Health plc (CLL.L)?

The following Wall Street research analysts have issued stock ratings on Cello Health plc (CLL.L) in the last twelve months:
View the latest analyst ratings for CLL.

What is the current price target for Cello Health plc (CLL.L)?

0 Wall Street analysts have set twelve-month price targets for Cello Health plc (CLL.L) in the last year. has the lowest price target set, forecasting a price of £100,000 for Cello Health plc (CLL.L) in the next year.
View the latest price targets for CLL.

What is the current consensus analyst rating for Cello Health plc (CLL.L)?

Cello Health plc (CLL.L) currently has from Wall Street analysts. The stock has a consensus analyst rating of "N/A."
View the latest ratings for CLL.

What other companies compete with Cello Health plc (CLL.L)?

How do I contact Cello Health plc (CLL.L)'s investor relations team?

Cello Health plc (CLL.L)'s physical mailing address is 11-13 Charterhouse Buildings, LONDON, EC1M 7AP, United Kingdom. The company's listed phone number is +44-20-78128460. The official website for Cello Health plc (CLL.L) is www.cellogroup.com.